NeuroPace (NPCE) EBITDA (2020 - 2026)

NeuroPace has reported EBITDA for 7 years, with the latest figure at -$5.1 million in Q2 2026.

• On a quarterly basis, EBITDA rose 37.2% year-over-year to -$5.1 million in Q2 2026; TTM through Jun 2026 was -$15.1 million, a 28.98% increase from a year earlier, with the FY2025 full-year figure at -$16.3 million, up 24.61% from the prior year.
• EBITDA was -$5.1 million for Q2 2026 at NeuroPace, up from -$5.6 million in the prior quarter.
• The five-year high for EBITDA was -$1.8 million in Q4 2025, with the low at -$11.0 million in Q2 2022.
• Average EBITDA over 5 years is -$6.6 million, with a median of -$6.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 151.99% in 2022, then surged 51.63% in 2025.
• Over 5 years, EBITDA stood at -$9.9 million in 2022, then surged by 48.77% to -$5.1 million in 2023, then climbed by 27.68% to -$3.7 million in 2024, then soared by 51.63% to -$1.8 million in 2025, then tumbled by 191.06% to -$5.1 million in 2026.
• The last three EBITDA figures came in at -$5.1 million (Q2 2026), -$5.6 million (Q1 2026), and -$1.8 million (Q4 2025), per Business Quant data.